Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells

Radiation Research

Volumn 162, Issue 6, 2004, Pages 623-634

  Mack, Philip C ^a,c   Jones, Angela A ^b   Gustafsson, Matthew H ^a,b   Gandara, David R ^a   Gumerlock, Paul H ^a   Goldberg, Zelanna ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; PROTEIN P53; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CLONOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA DAMAGE; DRUG DOSE REGIMEN; GENE SILENCING; HUMAN; HUMAN CELL; IONIZING RADIATION; IRRADIATION; LUNG NON SMALL CELL CANCER; NULL CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIATION; RADIATION DOSE; WILD TYPE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G2 PHASE; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; STAUROSPORINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9244260517     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3253     Document Type: Article

References (54)

1. R. T. Greenlee, M. B. Hill-Harmon, T. Murray and M. Thun, Cancer statistics, 2001. CA Cancer J. Clin. 51, 15-36 (2001).
2. A. Davies, D. R. Gandara, P. Lara, Z. Goldberg, P. Roberts and D. Lau, Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer. Semin. Oncol. 29, 10-16 (2002).
3. A. V. Gudkov and E. A. Komarova, The role of p53 in determining sensitivity to radiotherapy. Nat. Rev. Cancer 3, 117-129 (2003).
4. 2 arrest after DNA damage. Science 282, 1497-1501 (1998).
5. T. A. Chan, H. Hermeking, C. Lengauer, K. W. Kinzler and B. Vogelstein, 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401, 616-620 (1999).
6. 2/M checkpoint. Genes Dev. 14, 1584-1588 (2000).
7. T. Mitsudomi, T. Oyama, T. Kusano, T. Osaki, R. Nakanishi and T. Shirakusa, Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 85, 2018-2023 (1993).
8. P. Nurse, Universal control mechanism regulating onset of M-phase. Nature 344, 503-508 (1990).
9. T. K. MacLachlan, N. Sang and A. Giordano, Cyclins, cyclin-dependent kinases and cdk inhibitors: Implications in cell cycle control and cancer. Crit. Rev. Eukaryot. Gene Expr. 5, 127-156 (1995).
10. 2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277, 1501-1505 (1997).
11. Y. Sanchez, C. Wong, R. S. Thoma, R. Richman, Z. Wu, H. Piwnica-Worms and S. J. Elledge, Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25. Science 277, 1497-1501 (1997).
12. B. Furnari, N. Rhind and P. Russell, Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. Science 277, 1495-1497 (1997).
13. J. M. Brondello, M. N. Boddy, B. Furnari and P. Russell, Basis for the checkpoint signal specificity that regulates Chk1 and Cds1 protein kinases. Mol. Cell Biol. 19, 4262-4269 (1999).
14. 2/M DNA damage checkpoint. Genes Dev. 14, 1448-1459 (2000).
15. 2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett. 505, 7-12 (2001).
16. 1 checkpoint-competent cells. Cancer Res. 55, 1639-1642 (1995).
17. 2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 88, 956-965 (1996).
18. I. Takahashi, E. Kobayashi, K. Asano, M. Yoshida and H. Nakano, UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J. Antibiot. (Tokyo) 40, 1782-1784 (1987).
19. S. Akinaga, K. Gomi, M. Morimoto, T. Tamaoki and M. Okabe, Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res. 51, 4888-4892 (1991).
20. H. H. Xiao, Y. Makeyev, J. Butler, B. Vikram and W. A. Franklin, 7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines. Radiat. Res. 158, 84-93 (2002).
21. E. Tsuchida and M. Urano, The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma. Int. J. Radiat. Oncol. Biol. Phys. 39, 1153-1161 (1997).
22. L. Cartee, H. Sankala, C. Davis, R. Smith, S. Maggio, P. S. Lin, P. Dent and S. Grant, 7-Hydroxystaurosporine (UCN-01) and ionizing radiation combine to inhibit the growth of Bcl-2-overexpressing U937 leukemia cells through a non-apoptotic mechanism. Int. J. Oncol. 21, 351-359 (2002).
23. 2 checkpoint by the staurosporine derivative UCN-01 is associated with radiosensitisation in a subset of colorectal tumour cell lines. Br. J. Cancer 87, 352-358 (2002).
24. E. C. Busby, D. F. Leistritz, R. T. Abraham, L. M. Karnitz and J. N. Sarkaria, The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res. 60, 2108-2112 (2000).
25. P. R. Graves, L. Yu, J. K. Schwarz, J. Gales, E. A. Sausville, P. M. O'Connor and H. Piwnica-Worms, The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 275, 5600-5605 (2000).
26. B. Zhao, M. J. Bower, P. J. McDevitt, H. Zhao, S. T. Davis, K. O. Johanson, S. M. Green, N. O. Concha and B. B. Zhou, Structural basis for Chk1 inhibition by UCN-01. J. Biol. Chem. 277, 46609-46615 (2002).
27. 2-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res. 62, 5743-5748 (2002).
28. 2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the WeelHu kinase and activation of the Cdc25C phosphatase. J. Biol. Chem. 273, 33455-33464 (1998).
29. S. Akinaga, K. Nomura, K. Gomi and M. Okabe, Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol. 32, 183-189 (1993).
30. R. G. Shao, C. X. Cao, T. Shimizu, P. M. O'Connor, K. W. Kohn and Y. Pommier, Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. 57, 4029-4035 (1997).
31. 2-checkpoint inhibitor. Clin. Cancer Res. 2, 791-797 (1996).
32. A. Husain, X. J. Yan, N. Resales, C. Aghajanian, G. K. Schwartz and D. R. Spriggs, UCN-01 in ovary cancer cells: Effective as a single agent and in combination with cis-diamminedichloroplatinum(II) independent of p53 status. Clin. Cancer Res. 3, 2089-2097 (1997).
33. 2 arrest. Cancer Chemother. Pharmacol. 45, 252-258 (2000).
34. S. Abe, T. Kubota, Y. Otani, T. Furukawa, M. Watanabe, K. Kumai and M. Kitajima, UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA. Jpn. J. Cancer Res. 91, 1192-1198 (2000).
35. A. Monks, E. D. Harris, A. Vaigro-Wolff, C. D. Hose, J. W. Connelly and E. A. Sausville, UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Invest. New Drugs 18, 95-107 (2000).
36. 2 checkpoint abrogation. Int. J. Cancer 85, 703-709 (2000).
37. 2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents. Anticancer Res. 21, 23-28 (2001).
38. P. C. Mack, D. R. Gandara, A. H. Lau, P. N. Lara, Jr., M. J. Edelman and P. H. Gumerlock, Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother. Pharmacol. 51, 337-348 (2003).
39. J. Erenpreisa and M. S. Cragg, Mitotic death: A mechanism of survival? A review. Cancer Cell Int. 1, 1 (2001).
40. C. B. Jones, M. K. Clements, A. Redkar and S. S. Daoud, UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells. Int. J. Oncol. 17, 1043-1051 (2000).
41. ISVC. SAS Institute, Cary, NC, 1999.
42. P. C. Mack, D. R. Gandara, C. Bowen, M. J. Edelman, T. Paglieroni, J. B. Schnier, E. P. Gelmann and P. H. Gumerlock, RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. Clin. Cancer Res. 5, 2596-2604 (1999).
43. H. Willers, J. Dahm-Daphi and S. N. Powell, Repair of radiation damage to DNA. Br. J. Cancer 90, 1297-1301 (2004).
44. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res. 57, 1495-1501 (1997).
45. C. T. Hsueh, Y. C. Wu and G. K. Schwanz, UCN-01 suppresses E2F-1 mediated by ubiquitin-proteasome-dependent degradation. Clin. Cancer Res. 7, 669-674 (2001).
46. K. Kawakami, H. Futami, J. Takahara and K. Yamaguchi, UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem. Biophys. Res. Commun. 219, 778-783 (1996).
47. C. M. Seynaeve, M. Stetler-Stevenson, S. Sebers, G. Kaur, E. A. Sausville and P. J. Worland, Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res. 53, 2081-2086 (1993).
48. 1 phase checkpoint machinery. Jpn. J. Cancer Res. 92, 537-545 (2001).
49. H. Jiang and L. Y. Yang, Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: Association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins. Cancer Res. 59, 4529-4534 (1999).
50. S. Sato, N. Fujita and T. Tsuruo, Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21, 1727-1738 (2002).
51. E. A. Sausville. S. G. Arbuck, R. Messmann, D. Headlee, K. S. Bauer, R. M. Lush, A. Murgo, W. D. Figg, T. Lahusen and A. M. Senderowicz, Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol. 19, 2319-2333 (2001).
52. E. Fuse, H. Tanii, N. Kurata, H. Kobayashi, Y. Shimada, T. Tamura, Y. Sasaki, Y. Tanigawara, R. D. Lush and S. Kobayashi, Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res. 58, 3248-3253 (1998).
53. E. Fuse, A. Hashimoto, N. Sato, H. Tanii, T. Kuwabara, S. Kobayashi and Y. Sugiyama, Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid . glycoprotein. Pharm. Res. 17, 553-564 (2000).
54. A. M. Senderowicz, The cell cycle as a target for cancer therapy: Basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 7 (Suppl. 2), 12-19 (2002).